Browsing Tag
Capricor Therapeutics
5 posts
Greenstone Biosciences wins NHLBI R61 award to identify small-molecule treatments for DMD heart disease
Greenstone Biosciences has secured a $625,968 National Heart, Lung, and Blood Institute (NHLBI) R61 grant to combine patient-derived stem cells, proteomics and artificial intelligence in the search for small-molecule treatments for cardiac fibrosis in Duchenne muscular dystrophy (DMD). The award validates the company’s human-cell-based discovery platform, but target selection, compound validation and progression into the programme’s R33 phase remain critical tests.
Can Secretome Therapeutics turn its expanded leadership team into a Duchenne breakthrough?
Secretome Therapeutics has recruited experienced clinical, operational, medical affairs and finance executives as the private biotechnology company prepares to move STM-01 deeper into development for Duchenne muscular dystrophy-associated cardiomyopathy. The appointments indicate that Secretome is building the organisation required for late-stage trials and potential commercialisation, although the ultimate value of that infrastructure will depend on whether STM-01 produces convincing clinical evidence.
Capricor Therapeutics (NASDAQ: CAPR) reports sustained efficacy and safety in 4-year DMD trial of Deramiocel
Capricor Therapeutics reports 4-year HOPE-2 data for Deramiocel in Duchenne, showing cardiac stability and slowed muscle decline. Read how it may shape future FDA decisions.
Capricor Therapeutics advances deramiocel toward FDA approval with priority review
Capricor Therapeutics has reached a significant milestone in its efforts to develop a novel treatment for Duchenne muscular…
Capricor Therapeutics announces promising long-term results for deramiocel deramiocel in Duchenne muscular dystrophy
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company at the forefront of developing cell and exosome-based therapies, has shared…